Effect size analyses of Souvenaid in patients with Alzheimer’s disease

Manuscript Number: 

16-0745R1

Author(s): 
David A. Bennett, Paulo Henrique Bertolucci, Rafael Blesa, Jeffrey Cummings, John Harrison, Ian G. McKeith, Kenneth Rockwood, Philip Scheltens, Raj C. Shah, Wouter Wijker, David Wilkinson

Disclosures

David A. Bennett

  • Consulting Fees:
    Served as a co-United States Principal Investigator for the S-Connect study conducted by Nutricia Research; also served as a paid consultant to Nutricia to conduct independent analyses of S-Connect and Souvenir II studies, I serve on an adjudication committee for a clinical trial sponsored by Takeda, Inc.
    Lecture Fees:
    Nutricia funded a presentation to the XXV Brazil Neurological Congress. Goiania, Brazil. August 7, 2012.

Paulo Henrique Bertolucci

  • Consulting Fees:
    consultant - Novartis - per consultancy basis consultant - Support - per consultancy basis
    Lecture Fees:
    Novartis - Educational Program in Alzheimer Disease Support - Educational Program in Dementia and Nutrition

Rafael Blesa

  • Consulting Fees:
    Novartis, Janssen-Cilag, Lundbeck, Nutricia
    Lecture Fees:
    Novartis, Nutricia

Jeffrey Cummings

  • Consulting Fees:
    Dr. Cummings has provided consultation to Abbvie, Acadia, Accera, Actinogen, ADAMAS, Alkahest, Alzheon, Anavex, Astellas, Astra Zeneca, Avanir, Axovant, Biogen-Idec, Biotie, Boehinger-Ingelheim, Chase, Eisai, Forum, GE Healthcare, Genentech, Grifols, Intracellular Therapies, IRIS, Ionis Pharmaceuticals, Lilly, Lundbeck, MedAvante, Merck, Neurotrope, Novartis, Nutricia, Otsuka, Pfizer, Probiodrug, QR Pharma, Resverlogix, Roche, Servier, Sunovion, Suven, Takeda, Toyoma, Transition Therapeutics, and United Neuroscience.
    Equity:
    Dr. Cummings owns stock in ADAMAS, Prana, Sonexa, MedAvante, Neurotrax, and Neurokos.
    Patents/Royalties
    Dr. Cummings owns the copyright of the Neuropsychiatric Inventory (NPI)
    Grants
    • Agency: 
      Avanir
      Dates: 
      2015-2017

John Harrison

  • Consulting Fees:
    I have received consulting fees and and/or advisory board payments from the following companies and organisations in the past 2 years: AbbVie; Access to Quality; Amgen; Anavex; AstraZeneca; Avonex; Avraham; Axon; Axovant; Biogen Idec; Boehringer Ingelheim; Bracket; Catenion; CRF Health; DeNDRoN; Eisai; Eli Lilly; EnVivo Pharma; Enzymotec; ePharmaSolutions; Forum Pharma; GfHEu; Heptares; Janssen AI; Johnson & Johnson; Kaasa Health; Kyowa Hakko Kirin; Lundbeck; MedAvante; Merck; Mind Agilis; MyCognition; Neurim; Neurocog; Neurotrack; Novartis; Nutricia; Orion Pharma; Pfizer; Pharmanet/i3; Prana Biotech; PriceSpective; Probiodrug; Prophase; Prostrakan; Regeneron; Reviva; Roche; Sanofi; Servier; Shire; Takeda; TransTech Pharma and Velacor.
    Equity:
    Stock options in Neurotrack and a 50% share holding in Metis Cognition Ltd.
    Lecture Fees:
    Lundbeck, Medscape, Nutricia & Janssen.
    Patents/Royalties
    Patent for MyCognition technology. I receive royalties from Blackwell Scientific and Oxford University Press.

Ian G. McKeith

  • Consulting Fees:
    I chaired one advisory board for Nutricia in 2015 I consult with GE Heathcare, Takeda and with Axovant Sciences about DLB
    Lecture Fees:
    I have received lecture fees from GE Healthcare and Axovant Sciences

Kenneth Rockwood

  • Equity:
    DGI Clinical

Philip Scheltens

  • Consulting Fees:
    Dr Scheltens has acquired grant support (for the institution) from GE Healthcare, Danone Research, Piramal and MERCK. In the past 2 years he has received consultancy/speaker fees (paid to the institution) from Lilly, GE Healthcare, Novartis, Sanofi, Nutricia, Probiodrug, Biogen, Roche and EIP Pharma.

Raj C. Shah

  • Nothing to Disclose

Wouter Wijker

  • Patents/Royalties
    I work for a CRO (contract research organization), as such we conduct clinical research by commercial sponsors

David Wilkinson

  • Consulting Fees:
    £500, plus travel and accomodation expenses for attending Nutricia Advisory board in March 2016 I am now fully retired.